News

NE3107 added to levodopa enhances motor, non-motor benefits

Adding NE3107 to standard carbidopa/levodopa (CD/LD) therapy eases motor and non-motor symptoms in people with Parkinson’s disease, according to data from a Phase 2a trial. “These data suggest that NE3107 as an adjunct therapy to levodopa may hold promise in ameliorating specific non-motor symptoms of Parkinson’s Disease, particularly in sleep/fatigue…

High-intensity exercise can boost dopamine signaling in the brain

Participating in high-intensity exercise can help protect the brain from progressive damage in Parkinson’s disease, a proof-of-concept imaging study suggests. “This is the first time imaging has been used to confirm that the biology of the brain in those suffering with Parkinson’s disease is changed by intense exercise,” Evan…

Zambon gains exclusive rights to oral therapy IPX203 in Europe

Zambon Biotech has entered into an exclusive deal with Amneal Pharmaceuticals for rights to seek approval and commercialize the oral treatment IPX203 for Parkinson’s disease in the European Union, U.K., and Switzerland. IPX203 is an experimental extended-release formulation of carbidopa and levodopa, designed to ease…

Iowa researchers use music, movement for Parkinson’s patients

Researchers at Iowa State University are exploring the benefits of music and dance, along with other activities, for people with Parkinson’s disease. Studies have shown that regular physical exercise can ease Parkinson’s motor symptoms, and that dancing may improve or slow the advancement of both motor and…